Abstract:Background: Alzheimer disease (AD) affects at least 5 million individuals in the USA alone stimulating an intense search for disease prevention and treatment therapies as well as for diagnostic techniques allowing early identification of AD during a long pre-symptomatic period that can be used for the initiation of prevention trials of disease-modifying therapies in asymptomatic individuals.Methods: Our approach to developing such techniques is based on the Gradient Echo Plural Contrast Imaging (GEPCI) technique that provides quantitative in vivo measurements of several brain-tissue-specific characteristics of the gradient echo MRI signal (GEPCI metrics) that depend on the integrity of brain tissue cellular structure.Preliminary data were obtained from 34 participants selected from the studies of aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis. Cognitive status was operationalized with the Clinical Dementia Rating (CDR) scale. The participants, assessed as cognitively normal (CDR=O; n=23) or with mild AD dementia (CDR=0.5 or 1; n=11) underwent GEPCI MRI, a collection of cognitive performance tests and CSF amyloid (A beta) biomarker A beta(42). A subset of 19 participants also underwent PET PiB studies to assess their brain A beta burden. According to the Ap status, cognitively normal participants were divided into normal (A beta negative; n=13) and preclinical (A beta positive; n=10) groups.Results: GEPCI quantitative measurements demonstrated significant differences between all the groups: normal and preclinical, normal and mild AD, and preclinical and mild AD. GEPCI quantitative metrics characterizing tissue cellular integrity in the hippocampus demonstrated much stronger correlations with psychometric tests than the hippocampal atrophy. Importantly, GEPCI-determined changes in the hippocampal tissue cellular integrity were detected even in the hippocampal areas not affected by the atrophy.Our studies also uncovered strong correlations between GEPCI brain tissue metrics and beta-amyloid (A(3) burden defined by positron emission tomography (PET) - the current in vivo gold standard for detection of cortical All, thus supporting GEPCI as a potential surrogate marker for All imaging a known biomarker of early AD. Remarkably, the data show significant correlations not only in the areas of high A beta accumulation (e.g. precuneus) but also in some areas of medial temporal lobe (e.g. parahippocampal cortex), where A beta accumulation is relatively low.Conclusion: We have demonstrated that GEPCI provides a new approach for the in vivo evaluation of AD related tissue pathology in the preclinical and early symptomatic stages of AD. Since MRI is a widely available technology, the GEPCI surrogate markers of AD pathology have a potential for improving the quality of AD diagnostic, and the evaluation of new disease-modifying therapies.

Vascular-water-exchange MRI (VEXI) Enables the Detection of Subtle BBB Breakdown in Alzheimer’s Disease Without MRI Contrast Agent

Vascular-water-exchange MRI (VEXI) Enables the Detection of Subtle AXR Alterations in Alzheimer's Disease Without MRI Contrast Agent, Which May Relate to BBB Integrity.

Decoupling of Regional Cerebral Blood Flow and Brain Function along the Alzheimer's Disease Continuum.

White Matter Free Water Outperforms Cerebral Small Vessel Disease Total Score in Predicting Cognitive Decline in Persons with Mild Cognitive Impairment.

Imaging subtle leaks in the blood–brain barrier in the aging human brain: potential pitfalls, challenges, and possible solutions

Voxel-based analysis of cerebral perfusion changes in Alzheimer's disease using a novel 3D arterial spin-labeling technique

Associations of Alzheimer's Disease Pathology and Small Vessel Disease with Cerebral White Matter Degeneration: A Tract-Based MR Diffusion Imaging Study.

Application of T1-/T2-Weighted Ratio Mapping to Elucidate Intracortical Demyelination Process in the Alzheimer’s Disease Continuum

Disrupted Regional Cerebral Blood Flow, Functional Activity and Connectivity in Alzheimer’s Disease: A Combined ASL Perfusion and Resting State fMRI Study

In Vivo Detection of Microstructural Correlates of Brain Pathology in Preclinical and Early Alzheimer Disease with Magnetic Resonance Imaging.

Evaluation of apparent diffusion coefficient mappings in amnestic mild cognitive impairment using an image analysis software brain search

Mapping the Cerebrovascular Abnormality in Transgenic Alzheimer's Disease (AD) Mice with deep-learning-based super-resolution cerebral blood volume (CBV)-MRI

Non-invasive MRI of Blood-Cerebrospinal Fluid-Barrier Function: a Functional Biomarker of Early Alzheimer's Disease Pathology

Quantitative transport mapping of multi-delay arterial spin labeling MRI detects early blood perfusion alterations in Alzheimer's disease

Abstract TP25: Model-Free Dynamic Contrast-Enhanced MRI in Cerebral Small Vessel Disease: Test-Retest Reliability and Association With WMH Lesion Burden

Recent Advances in Arterial Spin Labeling Perfusion MRI in Patients with Vascular Cognitive Impairment

Microvascular Perfusion Imaging in Alzheimer's Disease

Correlation of blood–brain barrier leakage with cerebral small vessel disease including cerebral microbleeds in Alzheimer's disease

Amide proton transfer could be a surrogate imaging marker for predicting vascular cognitive impairment

Deep Microbleeds and Periventricular White Matter Disintegrity Are Independent Predictors of Attention/executive Dysfunction in Non-Dementia Patients with Small Vessel Disease.

Contribution of blood-brain barrier-related blood-borne factors for Alzheimer's disease vs. vascular dementia diagnosis: A pilot study